PAVmed regains Nasdaq $1 minimum bid compliance

PAVmed Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Accepted by SEC EDGAR 01/23/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

PAVmed Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq’s Listing Qualifications department notified the company on January 21, 2026 that its common stock now meets the $1 per share minimum bid price required under Nasdaq Listing Rule 5550(a)(2).

The company had previously been notified on January 23, 2025 that its stock had closed below $1 per share for 30 consecutive business days through January 22, 2025. Nasdaq has since determined that from January 2, 2026 to January 19, 2026, the closing bid price of PAVmed’s common stock was at or above $1 per share, bringing the company back into compliance and reducing the immediate risk of delisting from the Nasdaq Capital Market.

Positive

• PAVmed regains Nasdaq listing compliance by meeting the $1 minimum bid price requirement under Listing Rule 5550(a)(2), reducing the immediate risk of delisting from the Nasdaq Capital Market.

Negative

• None.

Insights

Equity market structure analyst

PAVmed removes immediate Nasdaq delisting risk by regaining the $1 bid price standard.

PAVmed received confirmation from Nasdaq on January 21, 2026 that it again complies with the Nasdaq Capital Market’s minimum bid price requirement. This follows a prior notice on January 23, 2025 that its common stock had traded below $1 per share for 30 consecutive business days through January 22, 2025, which had placed its listing status at risk.

Nasdaq later determined that, from January 2, 2026 to January 19, 2026, PAVmed’s closing bid price was at or above $1 per share, restoring compliance with Listing Rule 5550(a)(2). Maintaining this status keeps the company’s shares on the Nasdaq Capital Market, which can support liquidity and market visibility, though future listing status will depend on ongoing adherence to Nasdaq rules.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PAVmed Inc. (PAVM) announce in this 8-K filing?

PAVmed reported that Nasdaq’s Listing Qualifications department notified the company on January 21, 2026 that it has regained compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Why was PAVmed Inc. (PAVM) previously out of compliance with Nasdaq rules?

On January 23, 2025, PAVmed received a notice from Nasdaq stating that for the 30 consecutive business days through January 22, 2025, the closing bid price of its common stock was below the $1 per share minimum required for continued listing on the Nasdaq Capital Market.

How did PAVmed Inc. (PAVM) regain compliance with the Nasdaq $1 bid price rule?

Nasdaq determined that from January 2, 2026 to January 19, 2026, the closing bid price of PAVmed’s common stock was at $1 per share or greater, bringing the company back into compliance with Nasdaq Listing Rule 5550(a)(2).

What Nasdaq rule is referenced in PAVmed Inc.’s (PAVM) compliance notice?

The notice references Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share for a company’s common stock to remain listed on the Nasdaq Capital Market.

What does regaining Nasdaq minimum bid price compliance mean for PAVmed Inc. (PAVM) shareholders?

Regaining compliance with the $1 minimum bid price requirement means PAVmed’s common stock continues to qualify for listing on the Nasdaq Capital Market, avoiding the immediate risk of delisting that can affect trading liquidity and investor access.

Did PAVmed Inc. (PAVM) include any financial statements with this 8-K?

No financial statements were included; the filing primarily reports Nasdaq’s notification that PAVmed has regained compliance with the minimum bid price requirement and lists an exhibit for the cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001624326 0001624326 2026-01-21 2026-01-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 21, 2026

PAVMED INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-37685		47-1214177
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

360 Madison Avenue, 25th Floor, New York, New York		10017
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (917) 813-1828

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share		PAVM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 21, 2026, PAVmed Inc. (the “Company”) received a notification letter from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

As previously reported, on January 23, 2025, the Company had received a notification letter from the Listing Qualifications department stating that, for the prior 30 consecutive business days (through January 22, 2025), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Subsequently, Nasdaq determined that, from January 2, 2026 to January 19, 2026, the closing bid price of the Company’s common stock had been at $1 per share or greater. Accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 23, 2026	PAVMED INC.
	By:	/s/ Dennis McGrath
		Dennis McGrath
		President and Chief Financial Officer